Fresenius Kabi, LLC government contracts
$127M obligated across 5 federal awards. 2 are still running.
Who buys from Fresenius Kabi, LLC
| Agency | Awards | Obligated |
|---|---|---|
| Office of Assistant Secretary for Preparedness and Response | 3 | $124M |
| Defense Logistics Agency | 2 | $2.7M |
What Fresenius Kabi, LLC sells
Its awards by NAICS code. Codes with live notices link to them.
| Industry | Awards | Obligated |
|---|---|---|
| Pharmaceutical Preparation Manufacturing NAICS 325412 | 3 | $124M |
| Medicinal and Botanical Manufacturing NAICS 325411 | 2 | $2.7M |
Contracts ending soon
Awards that end in the next 18 months, soonest first. Expiring work is often recompeted.
| Award | Obligated | Start | End |
|---|---|---|---|
| ATROPINE 0.4MGML X 20ML SOLN. FOR INJ., MULTI-DOSE VIALS 8MG AND MIDAZOLAM SOLN. FOR INJ., 5MG/ML, MULTI-DOSE VIALS EO 14398 Office of Assistant Secretary for Preparedness and Response · 75A50326F80006 | $7.9M | Jul 30, 2026 | Jul 29, 2027 |
Largest awards
By total obligated value. Each links to its record on USAspending.gov.
| Award | Obligated | Start | End |
|---|---|---|---|
| BULK PHARMA - GROUP B (ASSET MGMT) ACYCLOVIR SODIUM SOLUTION, DOXYCYCLINE INJ., MEROPENEM, SODIUM CHLORIDE, STERILE WATER Office of Assistant Secretary for Preparedness and Response · 75A50325C00004 | $112M | Mar 14, 2025 | Mar 13, 2030 |
| ATROPINE 0.4MGML X 20ML SOLN. FOR INJ., MULTI-DOSE VIALS 8MG AND MIDAZOLAM SOLN. FOR INJ., 5MG/ML, MULTI-DOSE VIALS EO 14398 Office of Assistant Secretary for Preparedness and Response · 75A50326F80006 | $7.9M | Jul 30, 2026 | Jul 29, 2027 |
| BULK PHARMA DRUGS-FRESENIUS KABI Office of Assistant Secretary for Preparedness and Response · 75A50323C00011 | $4.7M | Feb 28, 2023 | Feb 29, 2024 |
| 8511525788!OTHER MEDICAL Defense Logistics Agency · SPE2D025F0535 | $1.4M | Jul 24, 2025 | Aug 31, 2026 |
| 8510030629!OTHER MEDICAL Defense Logistics Agency · SPE2D023F0548 | $1.3M | Jul 25, 2023 | Aug 26, 2024 |
Similar contractors
Companies winning under the same main NAICS code.
| Contractor | Awards | Obligated |
|---|---|---|
| Mckesson Corporation UEI S1RUKWWRYFL6 | 237 | $32.9B |
| Sanofi Vaccines US Inc. UEI NCXBGGQ8YTU9 | 8 | $310M |
| Chartwell RX LLC UEI ER5UA9TYBGH4 | 3 | $260M |
| Dla Troop Support UEI JSJMNWTKEJN3 | 3 | $241M |
| Exelan Pharmaceuticals Inc UEI FYZXNHSQTMG8 | 42 | $174M |
| Genentech USA, Inc UEI SA85BMHCTXK5 | 4 | $165M |
Stop checking this page by hand
Matched, not listed
Describe your company once. Captivaq scores every new notice against your capabilities, locations, and set-asides.
Earlier than the RFP
Forecasts and sources sought notices surface months before the solicitation, while you can still shape the win.
A draft, not a link
For the bids worth pursuing, it reads the solicitation and drafts the response with citations back to the source.
Questions people ask
What is Fresenius Kabi, LLC's UEI?
C2TRNWNQKMD6. The Unique Entity ID is the 12-character number SAM.gov assigns to every company that registers to do business with the federal government. It replaced the DUNS number in 2022.
How much has Fresenius Kabi, LLC won in federal contracts?
$127M obligated across 5 awards in Captivaq's records, most of it from Office of Assistant Secretary for Preparedness and Response. That covers contracts of $1M or more active since October 2023, so the full history is larger.
Which Fresenius Kabi, LLC contracts end soon?
1 award ends in the next 18 months, listed on this page. Expiring contracts are often recompeted, which is the opening for a competitor or a teaming partner.
Figures come from federal award records published on USAspending.gov: contracts of $1M or more active since October 2023, plus smaller awards tied to open opportunities. They are not a complete contract history; each award above links to its official record.
Captivaq is an independent service from Logesta Labs LLC and is not affiliated with or endorsed by the U.S. government or SAM.gov. The notice on the official source portal is the record that governs; confirm deadlines and amendments there.